The present invention relates to a novel compound inhibiting Hsp 90 and to a pharmaceutical composition including same as an active ingredient. Compounds of formula 1 and formula 2 according to the present invention inhibit the accumulation of HIF-1α protein, which is an Hsp90 client protein, by suppressing Hsp90 expression, and effectively inhibit the activity of vascular endothelial growth factor (VEGF). Furthermore, said compounds have low cytotoxicity and can thus be used as an active ingredient for the treatment of diabetic retinopathy and arthritis.Cette invention concerne un nouveau composé inhibant Hsp90 et une composition pharmaceutique le contenant à titre de principe actif. Les composés de formule 1 et de formule 2 selon l'invention inhibent l'accumulation de la protéineHIF-1α, qui est une protéine cliente d'Hsp90, par suppression de l'expression d'Hsp90, et inhibent efficacement l'activité du facteur de croissance endothélial vasculaire (VEGF). Lesdits composés ont en outre une basse cytotoxicité et peuvent par conséquent être utilisés à titre de principe actif pour traiter la rétinopathie diabétique et l'arthrite.본 발명은 Hsp90을 저해하는 신규한 화합물 및 이를 유효성분으로 함유하는 약학적 조성물에 관한 것으로, 본 발명에 따른 화학식 1 및 화학식 2의 화합물은 Hsp90 발현을 억제하여 Hsp90 클라이언트 단백질인 HIF-1α 단백질의 축적을 저해하고 신생 혈관 생성 인자(VEGF)의 활성을 효과적으로 저해할 뿐만 아니라, 세포독성도 낮으므로, 항암제, 당뇨병성 망망증 및 관절염 치료제의 유효성분으로 사용될 수 있다.
